North American Universities Seen Failing To Promote Socially Responsible Licensing 05/04/2013 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment A student group is holding top research universities in the US and Canada accountable for how much they are – or are not – contributing to global public health. According to a recently released report by Universities Allied for Essential Medicines, a non-profit organisation, most institutions are falling short when it comes to investing in neglected diseases and promoting access to medicines.
The Judgment In Novartis v. India: What The Supreme Court Of India Said 04/04/2013 by Intellectual Property Watch 9 Comments Following the Indian Supreme Court decision in Novartis AG v. Union of India, Prof. Frederick Abbott says, “the judgment is well-crafted, with close attention to the facts presented, and appears to take a balanced view of the matters brought before the Court.”
Australian Pharmaceutical Patents Review Draft Report Critical Of Patent Extensions, R&D Funding 03/04/2013 by Kelly Burke for Intellectual Property Watch Leave a Comment The Australian Pharmaceutical Patents Review yesterday issued its draft report, recommending that the Australian government reduce pharmaceutical patent extension terms and use estimated savings to subsidise research and development.
Novartis Loses Patent Bid: Lessons From India’s 3(d) Experience 01/04/2013 by Patralekha Chatterjee for Intellectual Property Watch 15 Comments New Delhi – On 1 April, in a packed room in India’s Supreme Court, two judges – Justice Aftab Alam and Justice Ranjana Desai – delivered a verdict that has the potential to dramatically change the national and global conversation about patents and patients.
India Dismisses Antitrust Complaint Against Gilead Sciences 01/04/2013 by Intellectual Property Watch Leave a Comment The Indian fair trade regulator has dismissed a complaint against biopharmaceutical company Gilead Sciences that alleged the company engaged in anti-competitive activities in the licensing of its anti-HIV drugs, according to the SpicyIP blog.
East African Community Doubles Efforts To Boost Local Pharmaceutical Production 28/03/2013 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment Arusha, Tanzania – Pharmaceutical manufacturers in East Africa have joined forces to strengthen their production capacity to meet at least half of the region’s demand for affordable, quality medicines. The East African Community is supporting this ambitious goal through various initiatives, including a regional intellectual property policy to guide partner states on developing national legislation that fosters local pharmaceutical production.
Biovision: Personalised Medicine, Climate Change, Sustainability Need Innovation 27/03/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment Lyon, France – Biovision, a biennial international event on life sciences, brought together some 3,000 participants this week to discuss and compare experiences in different fields, including personalised medicine, how best to use natural resources and the impact of climate change on food security. Open innovation was presented as a way forward, and the role of companies in mitigation was deemed important but with ethics.
Rules Changing For Life Sciences Tech Transfer, IP, Speakers Say 26/03/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment Lyon, France – Participants at a the Biovision international life sciences forum aimed at encouraging collaboration and integrating innovation shared experiences and discussed a number of topics including intellectual property strategy, technology transfer and the way forward for sustainable innovation.
Global Fund Receives USD 1.65B From US Congress; Names New Board Leadership 25/03/2013 by Intellectual Property Watch Leave a Comment The United States Congress on 21 March approved US$ 1.65 billion in aid and support for the Global Fund to Fight AIDS, Tuberculosis and Malaria, and US$ 4.07 billion for the US President’s Emergency Plan for AIDS Relief (PEPFAR). The Global Fund also announced a new Board chair and vice-chair.
US Supreme Court To Hear Arguments On Pay-For-Delay Drug Deals 23/03/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment The United States Supreme Court is scheduled to hear oral arguments on Monday in a case in which the US Federal Trade Commission is questioning payments made by brand name pharmaceutical companies to generic producers for delayed entry into the market of lower priced generics.